PenWest Tumbles On Clinical Study For Nalbuphine
Hub of the Universe — Shares of PenWest Pharmaceuticals toppled 20% to USD 4.30 Monday morn after the society released assorted results for a Phase IIa clinical trial for its drug nalbuphine ER, an intervention for continuing pain. PenWest informated that although the drug did non meet the study’s primary end, it made meet assorted secondary aces. As an upshot, PenWest plans to commence Phase IIb clinical trials for the ware in the latter part of 2008. The companionship added that it is searching a European merchandising partner, but plans to continue U.S. commercial rights.